Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to China SXT Pharmaceuticals, Inc.’s $10.2 Million U.S. Initial Public Offering
Press Release – New York, NY – January 4, 2019 – Sichenzia Ross Ference LLP congratulates China SXT Pharmaceuticals, Inc. (the “Company”) (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (“TCMPs”), on the final closing of its initial public offering on January 3, 2019. Together with the first closing on December 31, 2018, the Company raised approximately $10.2 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,546,275 ordinary shares at a public offering price of $4.00 per share. The shares are scheduled to commence trading on the NASDAQ Capital Market today at around 2:05 p.m. ET under the ticker symbol “SXTC.”
Boustead Securities, LLC acted as the sole underwriter for the offering and the Firm acted as legal counsel to the underwriter. The Sichenzia Ross Ference LLP team was led by Senior Partner and head of the Firm’s Asian Practice Group, Benjamin Tan.
“We are thrilled and honored to be part of China SXT Pharmaceuticals, Inc.’s successful IPO and offer our heartiest congratulations and best wishes to the Company,” said Mr. Benjamin Tan, Senior Partner at Sichenzia Ross Ference. “The completion of this successful IPO further cements Boustead Securities, LLC’s as an active leader in the US-China IPO field and we are proud to have represented them.”
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020
- Coronavirus (Covid 19) Update - March 16, 2020
- Founding Partner Gregory Sichenzia Featured in Law360 Article on Coronavirus-fueled Market Volatility - March 10, 2020